Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Israel Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Int J Dermatol. 2011 Aug;50(8):1014-9. doi: 10.1111/j.1365-4632.2010.04828.x.
Pemphigus vulgaris (PV) is a life-threatening disease affecting skin and mucous membranes. The "epitope spreading" theory posits that uncontrolled PV can gradually worsen because of exposure of cellular antigens to the immune system. To this end, high-dose systemic corticosteroids have been advocated as first-line treatment for patients with PV to achieve disease control.
To determine whether the initial dose of prednisone stratified by disease severity affects long-term disease severity.
A retrospective study was conducted on 58 patients with PV with at least five years of follow-up from diagnosis. Patients were categorized into three groups according to the initial dose of prednisone treatment. Parameters analyzed included age, gender, disease severity at baseline and follow-up, hospitalizations, prednisone doses and adjuvant therapy at follow-up, and remission rate.
Ten patients received initial low-dose prednisone or were treated initially without systemic CS, 19 patients received intermediate-dose prednisone, and 29 received high-dose prednisone. Disease severity at presentation correlated directly with initial prednisone doses. The duration of the first hospitalization and number of hospitalization days during the five-year follow-up period were significantly lower in the group treated with initial low-dose prednisone and similar for the groups treated with intermediate and high doses.
Disease severity of PV at presentation is a good predictor of the clinical course. Stratifying initial prednisone dose according to PV disease severity at presentation is appropriate.
寻常型天疱疮(PV)是一种危及生命的疾病,影响皮肤和粘膜。“表位扩展”理论认为,由于细胞抗原暴露于免疫系统,不受控制的 PV 可能会逐渐恶化。为此,高剂量全身皮质类固醇被提倡作为 PV 患者的一线治疗方法,以实现疾病控制。
确定根据疾病严重程度分层的泼尼松初始剂量是否会影响长期疾病严重程度。
对 58 例至少随访 5 年的 PV 患者进行回顾性研究。根据泼尼松治疗的初始剂量将患者分为三组。分析的参数包括年龄、性别、基线和随访时的疾病严重程度、住院情况、随访时的泼尼松剂量和辅助治疗以及缓解率。
10 例患者接受初始低剂量泼尼松或初始无全身 CS 治疗,19 例患者接受中剂量泼尼松治疗,29 例患者接受高剂量泼尼松治疗。初诊时疾病严重程度与初始泼尼松剂量直接相关。初始低剂量泼尼松治疗组的首次住院时间和五年随访期间的住院天数明显低于中剂量和高剂量治疗组。
初诊时 PV 的疾病严重程度是临床病程的良好预测指标。根据初诊时 PV 疾病严重程度分层初始泼尼松剂量是合适的。